ATE556721T1 - Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen - Google Patents

Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen

Info

Publication number
ATE556721T1
ATE556721T1 AT99960608T AT99960608T ATE556721T1 AT E556721 T1 ATE556721 T1 AT E556721T1 AT 99960608 T AT99960608 T AT 99960608T AT 99960608 T AT99960608 T AT 99960608T AT E556721 T1 ATE556721 T1 AT E556721T1
Authority
AT
Austria
Prior art keywords
intracellurary
delivery
compounds
nerve cells
compound
Prior art date
Application number
AT99960608T
Other languages
English (en)
Inventor
Robert Webb
Constance Mckee
Original Assignee
Manzanita Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manzanita Pharmaceuticals Inc filed Critical Manzanita Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE556721T1 publication Critical patent/ATE556721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/21—Hydrocarbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99960608T 1998-12-21 1999-11-29 Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen ATE556721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/217,037 US6652864B1 (en) 1998-12-21 1998-12-21 Compounds for intracellular delivery of therapeutic moieties to nerve cells
PCT/US1999/028211 WO2000037103A2 (en) 1998-12-21 1999-11-29 Compounds for intracellular delivery of therapeutic moieties to nerve cells

Publications (1)

Publication Number Publication Date
ATE556721T1 true ATE556721T1 (de) 2012-05-15

Family

ID=22809430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960608T ATE556721T1 (de) 1998-12-21 1999-11-29 Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen

Country Status (7)

Country Link
US (5) US6652864B1 (de)
EP (1) EP1140201B1 (de)
JP (1) JP2002532560A (de)
AT (1) ATE556721T1 (de)
AU (1) AU777207B2 (de)
CA (1) CA2356454A1 (de)
WO (1) WO2000037103A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
US20060280724A1 (en) * 2000-11-04 2006-12-14 Ferguson Ian A Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers
EP1349577A2 (de) * 2000-11-06 2003-10-08 Asilomar Pharmaceuticals, Inc. Intrazelluläre verabreichung von geladenen therapeutischen verbindungen an nervenzellen durch zielgerichtete proteine
EP1357928B1 (de) * 2000-11-16 2011-11-16 Shire LLC Neuartige pharmazeutische verbindung und verfahren zur herstellung und verwendung derselben
AU2002216864A1 (en) * 2000-12-21 2002-07-01 Mcgill University Conjugates of antibodies and anticancer drugs
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7338939B2 (en) 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
KR100822498B1 (ko) 2002-02-22 2008-04-16 샤이어 엘엘씨 규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US20080233049A1 (en) * 2004-06-23 2008-09-25 Ian Andrew Ferguson Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7662177B2 (en) 2006-04-12 2010-02-16 Bacoustics, Llc Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy
PL2308514T3 (pl) * 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP2646468B1 (de) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf-zusammensetzungen und ihre verwendung
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA3105879A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
JP2022553269A (ja) * 2019-10-23 2022-12-22 マンザニータ ファーマシューティカルズ，インコーポレーテッド ニューロトロフィン受容体結合コンジュゲート組成物、並びにその使用方法及び作製方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554498A (en) * 1896-02-11 Bottle
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US5232695A (en) * 1987-12-23 1993-08-03 G. D. Searle & Co. Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
WO1991008770A1 (en) 1989-12-11 1991-06-27 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
US5948384A (en) 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
AU1153692A (en) 1991-01-07 1992-08-17 St. George's Enterprises Limited Particulates
CA2116576C (en) 1991-08-30 2002-11-12 Aaron G. Filler Nucleic acid polymerase amplification
WO1993010234A1 (en) 1991-11-15 1993-05-27 The Regents Of The University Of California Therapy of central nervous system by genetically modified cells
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5502037A (en) 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
WO1995007092A1 (en) 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
JP3523879B2 (ja) * 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
US7144983B1 (en) * 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
GB9525180D0 (en) * 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
WO1997023608A1 (en) 1995-12-22 1997-07-03 Chiron Corporation Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements
US5767288A (en) 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes
US6406710B1 (en) * 1996-01-16 2002-06-18 Nikos Panayotatos Protein occlusion for delivery of small molecules
WO1997026275A1 (en) * 1996-01-16 1997-07-24 Nikos Panayotatos Protein occlusion for delivery of small molecules
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6486303B1 (en) * 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
EP1173192B1 (de) 1999-03-08 2018-08-15 Gerhart Graupner Verfahren und zusammensetzungen für eine gezielte verabreichung von medikamenten
EP1286700A2 (de) 2000-06-01 2003-03-05 Universite Catholique De Louvain Krebs aktivierte prodrugverbindungen

Also Published As

Publication number Publication date
CA2356454A1 (en) 2000-06-29
AU1746800A (en) 2000-07-12
EP1140201B1 (de) 2012-05-09
US20100266492A1 (en) 2010-10-21
JP2002532560A (ja) 2002-10-02
AU777207B2 (en) 2004-10-07
US7718605B2 (en) 2010-05-18
US20090124547A1 (en) 2009-05-14
WO2000037103A2 (en) 2000-06-29
US20050260211A1 (en) 2005-11-24
EP1140201A2 (de) 2001-10-10
US6887861B1 (en) 2005-05-03
US7678378B2 (en) 2010-03-16
US8138155B2 (en) 2012-03-20
US6652864B1 (en) 2003-11-25
WO2000037103A3 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
ATE556721T1 (de) Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen
TR200102800T2 (tr) Yeni bileşikler.
BR0111667A (pt) Novos compostos
GB9915437D0 (en) Chemical compounds III
BR0108678A (pt) Novos compostos
ITBO980572A0 (it) Dispositivo per la protezione dopo l' uso di un ago ipodermico , parti colarmente del tipo a farfalla .
BG106670A (en) April receptor (bcma) and uses thereof
WO2002013833A3 (en) SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2
CO5251404A1 (es) Compuestos antibioticos de azalida
DK1196396T3 (da) Farmakologisk aktive forbindelser med to kovalent bundne aktive principper (natrium-kanalblokker/P2Y2-receptoragonist) til behandling af slimhindeoverflader
BR0011856A (pt) Agonistas de receptor a2a de n-pirazol
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
SI1297013T1 (sl) Uporaba TACI kot protitumorskega sredstva
MXPA02012076A (es) Compuestos quimicos.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
MY137143A (en) Disposable diaper
BG103558A (en) Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
TW261615B (de)
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
TR200002580T2 (tr) Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
BR0111669A (pt) Novos compostos
MXPA02012472A (es) Compuestos quimicos.
TR199801659T2 (xx) Yeni triazolopurinler, haz�rlama y�ntemi, ila� olarak kullan�m�.